共 33 条
Brief Consent Methods Enable Rapid Enrollment in Acute Stroke Trial: Results From the TICH-2 Randomized Controlled Trial
被引:7
作者:
Law, Zhe Kang
[1
,6
]
Appleton, Jason P.
[1
,8
]
Scutt, Polly
[1
]
Roberts, Ian
[9
]
Salman, Rustam Al-Shahi
[10
]
England, Timothy J.
[2
]
Werring, David J.
[11
]
Robinson, Thompson
[12
,13
]
Krishnan, Kailash
[14
]
Dineen, Robert A.
[3
,15
]
Laska, Ann Charlotte
[16
]
Lyrer, Philippe A.
[17
,18
,19
]
Egea-Guerrero, Juan Jose
[20
]
Karlinski, Michal
[21
]
Christensen, Hanne
[22
,23
]
Roffe, Christine
[24
]
Bereczki, Daniel
[25
]
Ozturk, Serefnur
[26
]
Thanabalan, Jegan
[7
]
Collins, Ronan
[27
]
Beridze, Maia
[28
]
Ciccone, Alfonso
[29
]
Duley, Lelia
[4
]
Shone, Angela
[5
]
Bath, Philip M.
[1
,14
]
Sprigg, Nikola
[1
,14
]
机构:
[1] Univ Nottingham, Stroke Trials Unit, Nottingham, England
[2] Univ Nottingham, Vasc Med, Div Med Sci & Gem, Royal Derby Hosp Ctr, Nottingham, England
[3] Univ Nottingham, Radiol Sci, Nottingham, England
[4] Univ Nottingham, Nottingham Clin Trials Unit, Nottingham, England
[5] Univ Nottingham, Res & Innovat, Nottingham, England
[6] Natl Univ Malaysia, Dept Med, Bangi, Selangor, Malaysia
[7] Natl Univ Malaysia, Dept Surg, Div Neurosurg, Bangi, Selangor, Malaysia
[8] Univ Hosp Birmingham NHS Fdn Trust, Stroke, Birmingham, W Midlands, England
[9] London Sch Hyg & Trop Med, Clin Trials Unit, London, England
[10] Univ Edinburgh, Ctr Clin Brain Sci, Edinburgh, Midlothian, Scotland
[11] UCL Queen Sq Inst Neurol, Stroke Res Ctr, London, England
[12] Univ Leicester, Dept Cardiovasc Sci, Leicester, Leics, England
[13] Univ Leicester, NIHR Biomed Res Ctr, Leicester, Leics, England
[14] Nottingham Univ Hosp NHS Trust, Stroke, Nottingham, England
[15] NHIR Nottingham Biomed Res Ctr, Nottingham, England
[16] Karolinska Inst, Dept Clin Sci, Danderyd Hosp, Danderyd, Sweden
[17] Univ Hosp Basel, Dept Neurol, Basel, Switzerland
[18] Univ Hosp Basel, Stroke Ctr, Basel, Switzerland
[19] Univ Basel, Basel, Switzerland
[20] Virgen del Rocio Univ Hosp, NeuroCrit Care Unit, Seville, Spain
[21] Inst Psychiat & Neurol, Warsaw, Poland
[22] Bispebjerg Hosp, Dept Neurol, Copenhagen, Denmark
[23] Univ Copenhagen, Copenhagen, Denmark
[24] Keele Univ, Stroke Res, Sch Med, Newcastle Under Lyme, England
[25] Semmelweis Univ, Dept Neurol, Budapest, Hungary
[26] Selcuk Univ, Dept Neurol, Fac Med, Konya, Turkey
[27] Tallaght Univ Hosp, Age Related Hlth Care Stroke Serv, Dublin, Ireland
[28] Tbilisi State Med Univ, Univ Clin 1, Tbilisi, Georgia
[29] ASST Mantova, Poma Hosp, Neurol & Stroke Unit, Mantua, Italy
来源:
关键词:
cerebral hemorrhage;
humans;
informed consent;
logistic models;
lost to follow-up;
tranexamic acid;
SURROGATE DECISION-MAKERS;
ACUTE ISCHEMIC-STROKE;
INFORMED-CONSENT;
INTRACEREBRAL HEMORRHAGE;
CONSUMER INVOLVEMENT;
TRANEXAMIC ACID;
THROMBOLYSIS;
DESIGN;
D O I:
10.1161/STROKEAHA.121.035191
中图分类号:
R74 [神经病学与精神病学];
学科分类号:
摘要:
BACKGROUND: Seeking consent rapidly in acute stroke trials is crucial as interventions are time sensitive. We explored the association between consent pathways and time to enrollment in the TICH-2 (Tranexamic Acid in Intracerebral Haemorrhage-2) randomized controlled trial. METHODS: Consent was provided by patients or by a relative or an independent doctor in incapacitated patients, using a 1-stage (full written consent) or 2-stage (initial brief consent followed by full written consent post-randomization) approach. The computed tomography-to-randomization time according to consent pathways was compared using the Kruskal-Wallis test. Multivariable logistic regression was performed to identify variables associated with onset-to-randomization time of <= 3 hours. Results: Of 2325 patients, 817 (35%) gave self-consent using 1-stage (557; 68%) or 2-stage consent (260; 32%). For 1507 (65%), consent was provided by a relative (1 stage, 996 [66%]; 2 stage, 323 [21%]) or a doctor (all 2-stage, 188 [12%]). One patient did not record prerandomization consent, with written consent obtained subsequently. The median (interquartile range) computed tomography-to-randomization time was 55 (38-93) minutes for doctor consent, 55 (37-95) minutes for 2-stage patient, 69 (43-110) minutes for 2-stage relative, 75 (48-124) minutes for 1-stage patient, and 90 (56-155) minutes for 1-stage relative consents (P<0.001). Two-stage consent was associated with onset-to-randomization time of <= 3 hours compared with 1-stage consent (adjusted odds ratio, 1.9 [95% CI, 1.5-2.4]). Doctor consent increased the odds (adjusted odds ratio, 2.3 [1.5-3.5]) while relative consent reduced the odds of randomization <= 3 hours (adjusted odds ratio, 0.10 [0.03-0.34]) compared with patient consent. Only 2 of 771 patients (0.3%) in the 2-stage pathways withdrew consent when full consent was sought later. Two-stage consent process did not result in higher withdrawal rates or loss to follow-up. Conclusions: The use of initial brief consent was associated with shorter times to enrollment, while maintaining good participant retention. Seeking written consent from relatives was associated with significant delays.
引用
收藏
页码:1141 / 1148
页数:8
相关论文